Kintor Pharmaceutical logo

Kintor Pharmaceutical(SEHK) 9939

Market CapHK$789.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-93%
5 Year-97%
1 Year-30%
1 Month-20%
HK$1.51
-5.05%
-0.08Today
Kintor Pharmaceutical last closing stock price
MetricPriceDate
Last closeHKD 1.512026-10-15
Kintor Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.79%HKD 1.652026-10-08
1 month-19.95%HKD 1.882026-09-15
3 month-13.01%HKD 1.732026-07-17
Year to date-23.21%HKD 1.962025-12-31
1 year-30%HKD 2.152025-10-15
3 year-45.67%HKD 2.772023-10-16
5 year-96.51%HKD 43.102021-10-15
Since inception-92.56%HKD 21.502020-05-22

Kintor Pharmaceutical Financials at a Glance

Market Cap

HK$789.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥89.43M

Net Income (TTM)

-CN¥362.12M

EPS (TTM)

-HK$0.45

P/E Ratio

-3.51

Dividend

HK$0.00

Beta (Volatility)

0.00 (Low)

Price

HK$1.51

Volume

476,000

Open

HK$1.59

Previous Close

HK$1.59

Daily Range

HK$1.50 - HK$1.59

52-Week Range

HK$1.50 - HK$4.70

Estimated Earnings Date

Apr 1, 2027

9939 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kintor Pharmaceutical

Kintor Pharmaceutical Limited is a biotechnology firm focused on the discovery, development, and commercialization of innovative therapies. The company specializes in addressing androgen-receptor-related diseases, which present significant unmet medical needs, both in China and globally.

Products and Services
  • Proxalutamide: A second-generation androgen receptor antagonist for prostate cancer and COVID-19
  • Pyrilutamide: An AR antagonist targeting androgenetic alopecia and acne vulgaris
  • ALK-1 antibody: Designed for metastatic hepatocellular carcinoma and other solid tumors
Growth Outlook
  • Strong pipeline with multiple investigational products in various stages of development
  • Focus on significant unmet medical needs in oncology and dermatology markets
  • Potential for global market expansion as therapies progress through clinical trials
Financial Highlights
  • Recent quarterly revenue of CNY 51.32 million, showing growth from previous quarters
  • Trailing twelve months (TTM) revenue of CNY 26.25 million, indicating a developing revenue stream
  • Operating expenses reflect ongoing investment in research and development, crucial for future growth
Kintor Pharmaceutical Limited is positioned in a dynamic sector with a robust pipeline of products aimed at addressing critical health issues. The company's focus on androgen-receptor-related diseases aligns with significant market needs, providing a foundation for potential growth. Recent financial data indicates a developing revenue stream, supported by substantial investments in research and development. As the company continues to advance its therapies through clinical trials, it may capture opportunities in both domestic and international markets, appealing to investors interested in the biotechnology sector.
AI Generated • Oct 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

123

CEO

You Zhi Tong, PhD

Website

www.kintor.com.cn

Headquarters

Suzhou, JS 215123, CN

9939 Financials

Key Financial Metrics (TTM)

Gross Margin

12.57%

Operating Margin

-256.09%

Net Income Margin

-244.44%

Return on Equity

-129.93%

Return on Capital

-74.18%

Return on Assets

-59.47%

Earnings Yield

-28.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$789.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

497.98M

Volume

476.00K

Avg. Volume

848.74K

Financials (TTM)

Gross Profit

CN¥15.13M

Operating Income

-CN¥387.13M

EBITDA

-CN¥302.41M

Operating Cash Flow

-CN¥319.41M

Capital Expenditure

CN¥48.03M

Free Cash Flow

-CN¥271.38M

Cash & ST Invst.

CN¥31.79M

Total Debt

CN¥133.56M

Kintor Pharmaceutical Performance Analysis

Kintor Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 0N/A
20232023-12-31CNY 0N/A
20242024-12-31CNY 5,421,119N/A
20252025-12-31CNY 35,444,393553.8%
Kintor Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-3018.5%
Q42025-12-31308.3%
Q22026-06-3095.5%
Kintor Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -2.953.5%
20232023-12-31CNY -2.73-7.3%
20242024-12-31CNY -0.39-85.7%
20252025-12-31CNY -0.4823.4%
Kintor Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-16.7%
Q22025-06-309.5%
Q42025-12-31-31.6%
Q22026-06-3036.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥51.32M

N/A

Gross Profit

CN¥21.86M

+330.8%

Gross Margin

42.60%

N/A

Market Cap

HK$789.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$6.47M

N/A

Employees

122

N/A

Net Income

-CN¥74.74M

+3.5%

EBITDA

-CN¥62.02M

+0.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥31.79M

-90.5%

Total Debt

CN¥133.56M

-44.1%

Accounts Receivable

CN¥2.86M

N/A

Inventory

CN¥11.01M

+5403.0%

Long Term Debt

CN¥54.99K

-99.9%

Short Term Debt

CN¥133.50M

-25.4%

Return on Assets

-59.47%

N/A

Return on Invested Capital

-1.46%

N/A

Free Cash Flow

CN¥0.00

+100.0%

Operating Cash Flow

-CN¥49.99M

+58.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%

Questions About 9939

What is the current price of Kintor Pharmaceutical?

Kintor Pharmaceutical is trading at HK$1.51 per share.

What is the 52-week range for Kintor Pharmaceutical?

Over the past 52 weeks, Kintor Pharmaceutical has traded between HK$1.50 and HK$4.70.

How much debt does Kintor Pharmaceutical have?

As of the most recent reporting period, Kintor Pharmaceutical reported total debt of CN¥96.45M.

How much cash does Kintor Pharmaceutical have on hand?

Kintor Pharmaceutical reported CN¥38.72M in cash and cash equivalents in its most recent financial results.

What is Kintor Pharmaceutical’s dividend yield?

Kintor Pharmaceutical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services